Vibe Bioscience Ltd (TSE:VIBE)
:VIBE
Want to see TSE:VIBE full AI Analyst Report?
Top Page
Vibe Bioscience Ltd
(VIBE)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$0.04
▼(-36.67% Downside)
Action:ReiteratedDate:04/24/26
The score is held down primarily by weak financial strength—especially negative shareholders’ equity—and continued net losses with uneven cash-flow durability. Technicals show a short-term rebound but very overbought readings raise pullback risk, while valuation is difficult to support due to negative earnings and no stated dividend yield.
Positive Factors
Revenue Rebound
A 10.1% revenue rebound in 2025 signals recovering market demand and better top-line momentum versus prior down years. Sustained revenue growth supports scale economics, funds R&D or commercialization, and reduces dependence on external capital if maintained over multiple quarters.
Negative Factors
Negative Shareholders' Equity
Negative shareholders' equity reflects accumulated losses and a depleted capital base. This materially weakens financial flexibility, increases refinancing and dilution risk, constrains borrowing capacity, and makes the company more reliant on external capital to fund growth or cover setbacks.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Rebound
A 10.1% revenue rebound in 2025 signals recovering market demand and better top-line momentum versus prior down years. Sustained revenue growth supports scale economics, funds R&D or commercialization, and reduces dependence on external capital if maintained over multiple quarters.
Read all positive factors
Vibe Bioscience Ltd (VIBE) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$539.85K
Dividend YieldN/A
Average Volume (3M)6.19K
Price to Earnings (P/E)―
Beta (1Y)3.43
Revenue Growth38.01%
EPS Growth63.04%
CountryCA
Employees110
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.22
Shares Outstanding10,796,989
10 Day Avg. Volume10,465
30 Day Avg. Volume6,194
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.06
Price to Sales (P/S)0.02
P/FCF Ratio25.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vibe Bioscience Ltd Business Overview & Revenue Model
Company Description
Vibe Growth Corporation engages in the cultivation, production, retail, and distribution of cannabis for recreation and medicinal. The company operates five dispensaries, one distribution, and two cultivation operations, as well as sells its produ...
Vibe Bioscience Ltd Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
18
Very Negative
Cash Flow
27
Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 17.53M | 12.71M | 14.15M | 20.71M | 29.29M |
| Gross Profit | 6.95M | 4.74M | 5.17M | 6.49M | 8.42M |
| EBITDA | 1.43M | -3.91M | -8.42M | -3.63M | -1.11M |
| Net Income | -2.45M | -6.54M | -11.13M | -9.45M | -4.30M |
Balance Sheet | |||||
| Total Assets | 10.95M | 11.29M | 16.28M | 25.89M | 32.90M |
| Cash, Cash Equivalents and Short-Term Investments | 753.51K | 1.06M | 1.17M | 4.55M | 9.10M |
| Total Debt | 2.46M | 2.57M | 2.89M | 3.38M | 2.83M |
| Total Liabilities | 18.58M | 16.51M | 15.20M | 13.63M | 11.50M |
| Stockholders Equity | -7.63M | -5.22M | 1.08M | 12.26M | 21.39M |
Cash Flow | |||||
| Free Cash Flow | 17.18K | 202.82K | -2.78M | -3.71M | -7.20M |
| Operating Cash Flow | 63.61K | 233.74K | -2.71M | -1.97M | 848.73K |
| Investing Cash Flow | -46.43K | 19.02K | -71.80K | -1.75M | -8.43M |
| Financing Cash Flow | -334.53K | -360.37K | -595.55K | -699.14K | 14.33M |
Vibe Bioscience Ltd Technical Analysis
Negative
0.06
Price Trends
0.04
Negative
0.05
Negative
0.06
Negative
Market Momentum
>-0.01
Negative
34.56
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VIBE, the sentiment is Negative. The current price of 0.06 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and above the 200-day MA of 0.06, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 34.56 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:VIBE.
Vibe Bioscience Ltd Peers Comparison
UnderperformOutperform
Sector (51)
TSE:VIBE
Vibe Bioscience Ltd
0.05
0.00
0.00%
TSE:MLCL
Molecule Holdings
0.01
0.00
0.00%
TSE:GHG
Global Hemp
0.02
0.00
0.00%
TSE:ASIA
Asia Green Biotechnology Corp.
0.02
0.00
0.00%
TSE:XBRA
Xebra Brands Ltd.
0.01
-0.05
-83.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.